Tirzepatide Reduces Type 2 Diabetes Risk by 94% in Three-Year SURMOUNT-1 Study, Lilly Reports

SURMOUNT-1 results show a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three y...

November 14, 2024 | Thursday | News
FDA Grants Historic Approval to PTC Therapeutics’ KEBILIDI™—First Gene Therapy Directly Delivered to the Brain for AADC Deficiency

- First-ever FDA approval for gene therapy directly administered to the brain - - Priority review voucher granted - - Broad label including children an...

November 14, 2024 | Thursday | News
Ontada and Datavant Forge Strategic Collaboration to Accelerate Oncology Innovation Through Real-World Data Integration

 Ontada®, a McKesson business and leader in community oncology real-world data, clinical education, and point of care technologies, has ...

November 13, 2024 | Wednesday | News
23andMe CEO Anne Wojcicki Announces Major Restructuring with 40% Workforce Reduction and Shift Away from Therapeutics

Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commenc...

November 12, 2024 | Tuesday | News
Arcturus Therapeutics Receives FDA Green Light for Clinical Trial of sa-mRNA Vaccine Targeting Pandemic H5N1 Influenza

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focus...

November 12, 2024 | Tuesday | News
IDEAYA Secures Global Rights to Biocytogen’s Innovative BsADC Candidate, IDE034

IDEAYA Secures Exclusive Global License for Biocytogen’s First-In-Class BsADC, B7H3/PTK7 Topo-I Payload (IDE034), Validating Biocytogen’s Ren...

November 12, 2024 | Tuesday | News
ResQ Pharma Receives PDUFA Date for FDA Review of LipidRescue Kit for Life-Threatening Anesthetic Reactions

ResQ Pharma, Inc., a Chicago-based pharmaceutical company developing and commercializing innovative drug therapies, announced that it has received a P...

November 12, 2024 | Tuesday | News
Stamford Health First in Connecticut to Offer AI-Powered Cardiovascular Screening Tool

Stamford Health's Heart & Vascular Institute has announced it will be the first in Connecticut to offer a new, AI-powered cardiovas...

November 12, 2024 | Tuesday | News
Health Canada Approves Moderna’s mRESVIA™ RSV Vaccine for Adults 60 and Older

Moderna, Inc. (NASDAQ:MRNA) announced Health Canada has approved mRESVIA™ (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the ...

November 11, 2024 | Monday | News
AstraZeneca and Amgen’s Tezspire Shows Promising Phase III WAYPOINT Trial Results in Chronic Rhinosinusitis with Nasal Polyps

Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that...

November 11, 2024 | Monday | News
Fate Therapeutics Unveils Promising Preclinical Data for FT836, a Next-Generation iPSC-Derived CAR T-Cell Therapy Targeting MICA/B at SITC 2024

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripot...

November 12, 2024 | Tuesday | News
Aulisa® Medical USA Launches Flexible Leasing Options for Advanced Continuous Vital Sign Monitoring Solutions

Aulisa® Medical USA, Inc., a leader in FDA-cleared, wearable, wireless continuous vital sign monitoring technology, proudly announces the launch o...

November 08, 2024 | Friday | News
IASO Biotherapeutics’ Anti-BCMA CAR-T Therapy Fucaso™ Shows Strong Efficacy in Treating Relapsed/Refractory Multiple Myeloma in Phase 1b/2 Study Published in JAMA Oncology

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell ther...

November 08, 2024 | Friday | News
AstraZeneca Unveils Pioneering Haematology Research at ASH 2024, Highlighting Advancements in Cancer and Rare Disease Treatments

AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in haematology at the 66th Am...

November 08, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close